CURRICULUM VITAE – Prof. Ángel García

- Head of the Platelet Proteomics Group at the Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), Universidade de Santiago de Compostela, and the Instituto de Investigación Sanitaria de Santiago (IDIS). https://cimus.usc.gal/index.php/group/platelet-proteomics
- Associate Professor (*Profesor Titular*) at the Department of Pharmacology, University of Santiago de Compostela since December 2012. Previously, Ramón y Cajal Research Fellow at the University of Santiago de Compostela (2007-2012). Member of the BioFarma group at the Department of Pharmacology.
- Over 70 publications. More than 2000 citations. (Resource: ISI Web of Knowledge). H-index: 26 (July 2023)
- Editor of the book "Platelet proteomics: Principles, analysis and applications". Ángel García, Yotis A Senis (eds). Wiley & Sons, USA, 2011. ISBN: 978-0-470-46337.
- Executive Board member of the Spanish Proteomics Society (Sociedad Española de Proteómica). President for the period 2015-2019.
- Awards: Biochemistry Merit Awards 2001-02 / 2002-03 / 2004-05. Department of Biochemistry; University of Oxford. Research Prizes from the Spanish Society on Thrombosis and Haemostasis (SETH), 2013 and 2021.
- Associate editor of "Journal of Proteomics", and "Scientific Reports".
- Member of the International Society on Thrombosis and Haemostasis (ISTH), the Spanish Proteomics Society (SEProt), the Spanish Society on Thrombosis and Haemostasis (SETH), and the Spanish Society of Biochemistry and Molecular Biology (SEBBM).

The Platelet Proteomics group, led by Prof. Ángel García, belongs to the Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), Universidade de Santiago de Compostela, and the Instituto de Investigación Sanitaria de Santiago (IDIS) [Santiago Health Research Institute]. In our group, we are currently using a combination of Proteomics technology and classical biochemistry to unravel the signal transduction events following the activation of the most relevant platelet receptors. We are focusing our studies on healthy and diseased platelets in order to identify novel biomarkers and drug targets that may help to treat / diagnose those diseases related to a platelet hyperactivation state, such as acute coronary syndromes and obesity. We are also studying plasma extracellular vesicles as a source of biomarkers in the diseases mentioned above. In addition, we are currently searching for novel antiplatelet agents able to inhibit some of the most relevant drug targets identified by proteomics.